Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None202220212020 August 9, 2022 Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview June 21, 2022 Protara Therapeutics Announces Departure of Chief Financial Officer May 26, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting May 17, 2022 Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview March 2, 2022 Protara Therapeutics to Participate in Upcoming Investor Conferences February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer January 4, 2022 Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page › Last page » Displaying 1 - 12 of 53 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None202220212020 August 9, 2022 Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview June 21, 2022 Protara Therapeutics Announces Departure of Chief Financial Officer May 26, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting May 17, 2022 Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview March 2, 2022 Protara Therapeutics to Participate in Upcoming Investor Conferences February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer January 4, 2022 Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page › Last page » Displaying 1 - 12 of 53
August 9, 2022 Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview
May 26, 2022 Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
May 12, 2022 Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview
March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview
February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference
January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
